Stopping GLP-1 drugs: what actually happens when you quit semaglutide

What's this video probably claiming?

Based on the caption and the defensive tone of "FOR THE LAST TIME I'm not on Ozempic anymore," this creator is almost certainly addressing the classic social media accusation: that any visible weight loss must be GLP-1-assisted. The video likely involves the creator explaining they've stopped semaglutide, possibly defending maintained weight loss, and offering some version of how they transitioned off the drug. This framing opens up a cluster of common but frequently distorted claims: that stopping GLP-1 medications causes immediate weight regain, that results "don't count" if you used the drug, or conversely, that you can maintain losses easily once you've learned new habits. All of these are worth scrutinizing carefully before accepting at face value.

What does the science actually show?

The regain data on semaglutide discontinuation is genuinely sobering and not discussed nearly enough. The STEP 4 trial (Rubino et al., 2021, JAMA) followed patients who had achieved weight loss on 2.4 mg semaglutide weekly and then switched to placebo. Within 52 weeks of stopping, participants regained approximately two-thirds of their prior weight loss. Mean body weight reduction from baseline was 17.4% at the point of switching, and it rebounded to about 5% by week 120. A follow-up analysis confirmed that hunger hormone levels, particularly GIP and leptin sensitivity, largely reverted. The SURMOUNT-4 trial (Aronne et al., 2024, JAMA) showed similar patterns with tirzepatide. The biology here is not about willpower. GLP-1 receptors in the hypothalamus genuinely regulate appetite setpoints, and removing the agonist removes the signal.

Where does the social media noise diverge from clinical reality?

The noise cuts in two directions, both misleading. On one side, you have commenters insisting weight loss from GLP-1s is "fake" or temporary by default, which flattens what is actually a nuanced discontinuation curve. Some patients do maintain meaningful losses, particularly those who used the medication period to build muscle mass and sustainable dietary patterns. On the other side, creators sometimes imply that stopping a GLP-1 and keeping weight off proves the drug was unnecessary, which ignores selection bias completely. People who post success stories after stopping are not representative of the broader discontinuation population. Christou et al. (2019, Obesity Reviews) noted that post-discontinuation outcomes vary significantly based on baseline metabolic health, duration of treatment, and behavioral changes made during treatment. One TikTok video cannot tell you which category someone falls into.

What should you actually know?

GLP-1 receptor agonists like semaglutide are approved long-term medications, not short courses. The FDA label for Wegovy does not specify a stop date. Treating them like a diet you "finish" misrepresents how the drug class works mechanically. That said, some patients do discontinue for legitimate reasons: cost, side effects, access, or in consultation with a prescriber after stabilizing metabolic markers. If you or someone you know is considering stopping a GLP-1, the conversation should happen with a licensed clinician who can assess individual risk of regain, adjust other interventions, and monitor metabolic markers like fasting glucose and lipids. Anecdotal TikTok outcomes, however compelling, are not a substitute for that process. The creator's personal experience is real but not generalizable to your physiology.